echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first imitation of Haisco's "ranolazine sustained-release tablets" was launched

    The first imitation of Haisco's "ranolazine sustained-release tablets" was launched

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 8, according to the official website of CDE, Haisco Pharmaceuticals applied for the listing of the 3 generic ranolazine sustained-release tablets (acceptance number: CYHS2101986/7)


    Source: CDE official website

    Ranolazine was developed by Gilead and is the first drug approved by the FDA for the treatment of chronic angina pectoris in the past decade.


    According to the Insight database, ranolazine global sales reached a peak of US$758 million in 2018.


    Ranolazine global sales

    Source: Insight database (http://db.


    Ranolazine has not yet been marketed in China.


    Ranolazine variety competition details (Insight)

    Source: Insight database (http://db.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.